Angitia Biopharmaceuticals
Updated: February 05, 2026
CEO - Hua Zhu (David) Ke
Country: China | Funding: $406M (+)
Founded: 2018
Website: https://www.angitiabio.com/
Angitia Biopharmaceuticals develops therapies for the treatment of serious musculoskeletal disorders. It's currently conducting clinical trials of three biologic drug candidates for the treatment of osteoporosis, osteogenesis imperfecta (OI) and spinal fusion. Its flagship candidates are bispecific antibodies targeting sclerostin and DKK1, key negative regulators of Wnt signaling in bone tissue. Neutralization of sclerostin and DKK1 can stimulate bone formation and inhibit bone resorption. Together, these mechanisms may lead to increased bone mineral density.
Founded: 2018
Website: https://www.angitiabio.com/
Angitia Biopharmaceuticals develops therapies for the treatment of serious musculoskeletal disorders. It's currently conducting clinical trials of three biologic drug candidates for the treatment of osteoporosis, osteogenesis imperfecta (OI) and spinal fusion. Its flagship candidates are bispecific antibodies targeting sclerostin and DKK1, key negative regulators of Wnt signaling in bone tissue. Neutralization of sclerostin and DKK1 can stimulate bone formation and inhibit bone resorption. Together, these mechanisms may lead to increased bone mineral density.
